[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619506":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":35,"responsibleParty":49,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Jinnah Postgraduate Medical Centre","OTHER_GOV",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (TRIPLE COMBINATION THERAPY GROUP)","ACTIVE_COMPARATOR","Triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%) applied nightly for 12 weeks. All participants also used broad-spectrum sunscreen (SPF ≥30) during daytime.",[13,14],"Drug: Triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)","Drug: Broad-spectrum sunscreen (SPF ≥30)",{"label":16,"type":17,"description":18,"interventionNames":19},"Group B ( METFORMIN 30% GEL THERAPY GROUP )","EXPERIMENTAL","Participants will apply 30% metformin gel topically to melasma-affected areas once nightly for 12 weeks. All participants will also use broad-spectrum sunscreen (SPF ≥30) during daytime.",[20,14],"Drug: Metformin gel, 30%",[22,27,31],{"type":23,"name":24,"description":18,"armGroupLabels":25,"otherNames":26},"DRUG","Metformin gel, 30%",[16],null,{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)","Topical triple combination cream containing hydroquinone 2%, tretinoin 0.025%, and fluocinolone acetonide 0.01%, applied once nightly to affected facial areas for 12 weeks",[9],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Broad-spectrum sunscreen (SPF ≥30)","Applied during daytime throughout the 12-week treatment period (both arms)",[9,16],[36],{"facility":37,"status":26,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":26},"JPMC","Karachi","Sindh","7550","Pakistan","PK",{"type":44,"coordinates":45},"Point",[46,47],67.0104,24.8608,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr Summiya Shakeel Ahmed","FCPS part 2 Trainee dermatology","100619506","comparison-of-efficacy-of-metformin-gel-30-vs-triple-combination-cream-hydroquinone-4-flucinolone-acetonide-001-tretinoin-0025-in-treatment-of-melasma-in-tertiary-care-hospital-karachi-100619506",false,"NCT07345507","Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi","Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi.","Inclusion Criteria:\n\n* Adults aged 18- 60 years of either gender.\n* Diagnosed with melasma based on clinical examination and Wood's lamp assessment.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Patients with a history of hypersensitivity to any study medication components.\n* Patients currently on other melasma treatments or those with other dermatologic conditions affecting pigmentation.","ALL","18 Years","60 Years",{"count":64,"type":65},34,"ACTUAL","INTERVENTIONAL",[68],"NA","This study will compare two topical treatments for melasma. Participants will be randomly assigned to receive either triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%) or 30% metformin gel, applied once nightly for 12 weeks. All participants will use broad-spectrum sunscreen (SPF ≥30) during the daytime throughout the treatment period. Melasma severity will be assessed using the Melasma Area and Severity Index (MASI), and the study will determine which treatment is more effective and better tolerated at the end of 12 weeks.",[71],"Melasma",[71,73,74,75,76],"Efficacy","METFORMIN GEL","HYDROQUINONE 2%","TRETINOIN 0.025%","COMPLETED","2026-01-19",{"date":80,"type":65},"2026-01-21",{"date":82,"type":65},"2025-02-01",{"date":84,"type":65},"2025-08-30",{"name":5,"class":6},1]